Exploring Multivalency in the Development of Anti-PD-L1 Peptides for Cancer Immunotherapy
Pharmaceutical Research · 2024
DOI: 10.1007/s11095-024-03803-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Research, 2024. Verfasst von Umar-Farouk Mamani und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, 2464 Charlotte Street, Kansas City, MO,…. Hauptthemen laut MEDLINE: B7-H1 Antigen, Peptides, Immunotherapy, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NCI NIH HHS, NIAAA NIH HHS.
Abstract (Originalsprache)
PURPOSE: The PD-1/PD-L1 pathway is one of the most effective immune checkpoint pathways utilized for cancer immunotherapy. Despite the success of anti-PD-1/PD-L1 mAbs, there is growing interest in developing low molecular weight anti-PD-1/PD-1 agents, such as peptides, because of their improved tumor penetration. We recently developed a small anti-PD-L1 peptide and demonstrated its promising anti-tumor activity. In this study, we investigate multivalency as a strategy to increase the binding avidity and blocking efficiency of the anti-PD-L1 peptide. METHODS: Multivalent peptide inhibitors are designed with multiple copies of a peptide inhibitor in a single molecule. We synthesized peptides with different valences and examined their activity. We also investigated how spacer length affects the activity of these multivalent peptides. RESULTS: Using this strategy, we developed a multivalent peptide that demonstrated approximately 40 times higher blocking efficiency and improved stability compared to the original peptide. Increasing the valency enhanced the peptide's specificity, which is essential for minimizing side effects. CONCLUSIONS: Multivalency approach represents a promising platform for improving the efficacy of peptide-based checkpoint inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, 2464 Charlotte Street, Kansas City, MO, 64108, USA.
- Division of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, 2464 Charlotte Street, Kansas City, MO, 64108, USA. chengkun@umkc.edu.
Förderung
- NIH HHS
- NCI NIH HHS
- NIAAA NIH HHS
- NIH
Zitieren
APA
Mamani, U. F., Ibrahim, M. N., Liu, Y., Fetse, J., Lin, C. Y., Kandel, S., Nakhjiri, M., Koirala, S., Guo, Y., Alahmari, M., & Cheng, K. (2024). Exploring Multivalency in the Development of Anti-PD-L1 Peptides for Cancer Immunotherapy. Pharmaceutical Research. https://doi.org/10.1007/s11095-024-03803-1
Vancouver
Mamani UF, Ibrahim MN, Liu Y, Fetse J, Lin CY, Kandel S, et al. Exploring Multivalency in the Development of Anti-PD-L1 Peptides for Cancer Immunotherapy. Pharmaceutical Research. 2024. doi:10.1007/s11095-024-03803-1
BibTeX
@article{Mamani2024,
author = {Mamani, Umar-Farouk and Ibrahim, Mohammed Nurudeen and Liu, Yanli and Fetse, John and Lin, Chien-Yu and Kandel, Sashi and Nakhjiri, Maryam and Koirala, Sushil and Guo, Yuhan and Alahmari, Mohammed and Cheng, Kun},
title = {Exploring Multivalency in the Development of Anti-PD-L1 Peptides for Cancer Immunotherapy},
journal = {Pharmaceutical Research},
year = {2024},
doi = {10.1007/s11095-024-03803-1}
}
EUVIMED